Mantle cell lymphoma is an aggressive tumor for which new drugs targeting underlying molecular mechanisms are opening promising avenues. A recent study has elucidated the basis for targeting B cell receptor signaling in these lymphomas and identified somatic mutations in NF-κB regulatory genes that confer resistance to this therapy.
